Ewing sarcoma from molecular biology to the clinic

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Genetics

Background:

• Ewing sarcoma (ES) is the second most common primary bone tumor in children, adolescents, and young adults in Europe.
• Conventional treatments combining chemotherapy and surgery yield a 70% survival rate for localized disease, but less than 30% for resistant or metastatic cases.
• Limited progress in survival rates over recent decades underscores the urgent need for innovative therapeutic strategies.

Purpose of the Study:

• To provide a comprehensive overview of Ewing sarcoma (ES).
• To describe the clinical, cellular, and molecular aspects of ES.
• To highlight the genetic underpinnings and the role of the EWS-FLI1 fusion protein.

Main Methods:

• Review of clinical and biological data on Ewing sarcoma.
• Analysis of genetic characteristics, particularly chromosomal translocations.
• Description of the EWS-FLI1 fusion protein's oncogenic role.

Main Results:

• Ewing sarcoma (ES) is characterized by specific chromosomal translocations.
• The EWS-FLI1 fusion protein, resulting from the (11; 22) translocation in 85% of cases, is a key oncogenic driver.
• Understanding these molecular aspects is critical for developing targeted therapies.

Conclusions:

• The EWS-FLI1 fusion protein is central to ES pathogenesis.
• Further research into the molecular mechanisms of ES is essential for improving patient outcomes.
• Novel therapeutic approaches targeting the EWS-FLI1 pathway are needed.